Identification of Adipokine Clusters Related to Parameters of Fat Mass, Insulin Sensitivity and Inflammation

In obesity, elevated fat mass and ectopic fat accumulation are associated with changes in adipokine secretion, which may link obesity to inflammation and the development of insulin resistance. However, relationships among individual adipokines and between adipokines and parameters of obesity, glucose metabolism or inflammation are largely unknown. Serum concentrations of 20 adipokines were measured in 141 Caucasian obese men (n = 67) and women (n = 74) with a wide range of body weight, glycemia and insulin sensitivity. Unbiased, distance-based hierarchical cluster analyses were performed to recognize patterns among adipokines and their relationship with parameters of obesity, glucose metabolism, insulin sensitivity and inflammation. We identified two major adipokine clusters related to either (1) body fat mass and inflammation (leptin, ANGPTL3, DLL1, chemerin, Nampt, resistin) or insulin sensitivity/hyperglycemia, and lipid metabolism (vaspin, clusterin, glypican 4, progranulin, ANGPTL6, GPX3, RBP4, DLK1, SFRP5, BMP7, adiponectin, CTRP3 and 5, omentin). In addition, we found distinct adipokine clusters in subgroups of patients with or without type 2 diabetes (T2D). Logistic regression analyses revealed ANGPTL6, DLK1, Nampt and progranulin as strongest adipokine correlates of T2D in obese individuals. The panel of 20 adipokines predicted T2D compared to a combination of HbA1c, HOMA-IR and fasting plasma glucose with lower sensitivity (78% versus 91%) and specificity (76% versus 94%). Therefore, adipokine patterns may currently not be clinically useful for the diagnosis of metabolic diseases. Whether adipokine patterns are relevant for the predictive assessment of intervention outcomes needs to be further investigated.

[1]  J. Chudek,et al.  Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome , 2014, Clinical endocrinology.

[2]  Jennifer R. Harris,et al.  The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies , 2014, BMC Endocrine Disorders.

[3]  Karel G M Moons,et al.  Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. , 2014, The lancet. Diabetes & endocrinology.

[4]  H. Randeva,et al.  Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. , 2013, The Journal of clinical endocrinology and metabolism.

[5]  P. Scherer,et al.  Adiponectin, driver or passenger on the road to insulin sensitivity? , 2013, Molecular metabolism.

[6]  M. Blüher.  Adipose tissue dysfunction contributes to obesity related metabolic diseases. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[7]  H. J. Yoo,et al.  Implication of Progranulin and C1q/TNF-Related Protein-3 (CTRP3) on Inflammation and Atherosclerosis in Subjects with or without Metabolic Syndrome , 2013, PloS one.

[8]  Zhengai Xiong,et al.  Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. , 2013, The Journal of clinical endocrinology and metabolism.

[9]  C. Kahn,et al.  Glypican-4 Enhances Insulin Signaling via Interaction With the Insulin Receptor and Serves as a Novel Adipokine , 2012, Diabetes.

[10]  M. Green,et al.  Association between serum retinol-binding protein 4 concentrations and clinical indices in subjects with type 2 diabetes: a meta-analysis. , 2012, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[11]  E. Benjamin,et al.  Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study , 2012, Diabetology & Metabolic Syndrome.

[12]  P. Scherer,et al.  Adiponectin: mechanistic insights and clinical implications , 2012, Diabetologia.

[13]  M. Fasshauer,et al.  Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. , 2012, Metabolism: clinical and experimental.

[14]  M. Stampfer,et al.  Two Patterns of Adipokine and Other Biomarker Dynamics in a Long-Term Weight Loss Intervention , 2012, Diabetes Care.

[15]  S. Kitazawa,et al.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. , 2012, Cell metabolism.

[16]  S. Hartwig,et al.  Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders , 2012, Proteomics. Clinical applications.

[17]  H. Park,et al.  Relationship between vaspin gene expression and abdominal fat distribution of Korean women. , 2011, Endocrine journal.

[18]  Bing Chen,et al.  Serum bone morphogenetic protein 7, insulin resistance, and insulin secretion in non-diabetic individuals. , 2011, Diabetes research and clinical practice.

[19]  L. Lynch,et al.  Preadipocyte factor-1 is associated with metabolic profile in severe obesity. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  G. Kottas,et al.  Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[21]  C. Liapis,et al.  Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[22]  M. Laakso,et al.  A novel surrogate index for hepatic insulin resistance , 2011, Diabetologia.

[23]  E. Wijsman,et al.  Low Clusterin Levels in High-Density Lipoprotein Associate With Insulin Resistance, Obesity, and Dyslipoproteinemia , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Fasshauer,et al.  Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes , 2010, PloS one.

[25]  H. Randeva,et al.  Metformin Treatment May Increase Omentin-1 Levels in Women With Polycystic Ovary Syndrome , 2010, Diabetes.

[26]  M. Fasshauer,et al.  Insulin-sensitive obesity. , 2010, American journal of physiology. Endocrinology and metabolism.

[27]  K. Kristiansen,et al.  Cross Talk between Insulin and Bone Morphogenetic Protein Signaling Systems in Brown Adipogenesis , 2010, Molecular and Cellular Biology.

[28]  J. Moreno-Navarrete,et al.  Circulating omentin concentration increases after weight loss , 2010, Nutrition & metabolism.

[29]  W. Rathmann,et al.  Prevalence of undiagnosed diabetes and impaired glucose regulation in 35–59‐year‐old individuals in Southern Germany: the KORA F4 Study , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[30]  J. Mauer,et al.  Visfatin/PBEF/Nampt and Resistin Expressions in Circulating Blood Monocytes are Differentially Related to Obesity and Type 2 Diabetes in Humans , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[31]  Massimo Midiri,et al.  Visceral Adiposity Index , 2010, Diabetes Care.

[32]  Puy Garrastachu,et al.  BAT: a new target for human obesity? , 2009, Trends in pharmacological sciences.

[33]  H. Randeva,et al.  Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin , 2009, Diabetes.

[34]  M. Blüher,et al.  Adipose tissue dysfunction in obesity. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[35]  M. Fasshauer,et al.  Serum Progranulin Concentrations May Be Associated With Macrophage Infiltration Into Omental Adipose Tissue , 2009, Diabetes.

[36]  C. Kahn,et al.  New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure , 2008, Nature.

[37]  H. Randeva,et al.  Metformin Decreases the Adipokine Vaspin in Overweight Women With Polycystic Ovary Syndrome Concomitant With Improvement in Insulin Sensitivity and a Decrease in Insulin Resistance , 2008, Diabetes.

[38]  R. Rabasa-Lhoret,et al.  Metabolically healthy but obese women: effect of an energy-restricted diet , 2008, Diabetologia.

[39]  G. Bray,et al.  Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program , 2008, Diabetes.

[40]  M. Fasshauer,et al.  Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes , 2008, Diabetes.

[41]  P. Zimmet,et al.  Chemerin is a novel adipokine associated with obesity and metabolic syndrome. , 2007, Endocrinology.

[42]  E. Butcher,et al.  Chemerin, a Novel Adipokine That Regulates Adipogenesis and Adipocyte Metabolism* , 2007, Journal of Biological Chemistry.

[43]  M. Fasshauer,et al.  Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. , 2007, Cell metabolism.

[44]  A. Shuldiner,et al.  Omentin Plasma Levels and Gene Expression Are Decreased in Obesity , 2007, Diabetes.

[45]  P. Kern,et al.  Ectopic fat accumulation and metabolic syndrome , 2007, Diabetes, obesity & metabolism.

[46]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[47]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[48]  Arya M. Sharma,et al.  Retinol-Binding Protein 4 in Human Obesity , 2006, Diabetes.

[49]  B. Heude,et al.  Serum adiponectin is related to plasma high-density lipoprotein cholesterol but not to plasma insulin-concentration in healthy children: the FLVS II study. , 2006, Metabolism: clinical and experimental.

[50]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[51]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[52]  Jacqueline Capeau,et al.  Recent advances in the relationship between obesity, inflammation, and insulin resistance. , 2006, European cytokine network.

[53]  R. Ross,et al.  Visceral Fat Is an Independent Predictor of All‐cause Mortality in Men , 2006, Obesity.

[54]  M. Fasshauer,et al.  Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. , 2006, Biochemical and biophysical research communications.

[55]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[56]  Eijiro Watanabe,et al.  Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Marc Parmentier,et al.  Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids , 2003, The Journal of experimental medicine.

[58]  T. Saruta,et al.  Correlation between serum resistin level and adiposity in obese individuals. , 2003, Obesity research.

[59]  H. Boeing,et al.  Adiponectin and protection against type 2 diabetes mellitus , 2003, The Lancet.

[60]  G. Gallus,et al.  Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.

[61]  R. Paschke,et al.  Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. , 2002, Biochemical and biophysical research communications.

[62]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[63]  S. O’Rahilly,et al.  The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.

[64]  E. Ferrannini,et al.  Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). , 1997, The Journal of clinical investigation.